Search Results - "Anton Torres, Antonio"

Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review by Lao, Juan, Madani, Julia, Puértolas, Teresa, Álvarez, María, Hernández, Alba, Pazo-Cid, Roberto, Artal, Ángel, Antón Torres, Antonio

“…Drug delivery systems can provide enhanced efficacy and/or reduced toxicity for anticancer agents. Liposome drug delivery systems are able to modify the…”
Get full text

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer by Alba, Emilio, Lluch, Ana, Ribelles, Nuria, Anton‐Torres, Antonio, Sanchez‐Rovira, Pedro, Albanell, Joan, Calvo, Lourdes, García‐Asenjo, Jose Antonio Lopez, Palacios, Jose, Chacon, Jose Ignacio, Ruiz, Amparo, De la Haba‐Rodriguez, Juan, Segui‐Palmer, Miguel A., Cirauqui, Beatriz, Margeli, Mireia, Plazaola, Arrate, Barnadas, Agusti, Casas, Maribel, Caballero, Rosalia, Carrasco, Eva, Rojo, Federico

“…Background. In the neoadjuvant setting, changes in the proliferation marker Ki67 are associated with primary endocrine treatment efficacy, but its value as a…”
Get full text

Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer by Wardley, Andrew M, Pivot, Xavier, Morales-Vasquez, Flavia, Zetina, Luis M, de Fátima Dias Gaui, Maria, Reyes, Douglas Otero, Jassem, Jacek, Barton, Claire, Button, Peter, Hersberger, Veronica, Torres, Antonio Antón

“…PURPOSE To evaluate trastuzumab (H) and docetaxel (T) with or without capecitabine (X) as first-line combination therapy for human epidermal growth factor…”
Get full text

Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial by André, Thierry, Berton, Dominique, Curigliano, Giuseppe, Sabatier, Renaud, Tinker, Anna V, Oaknin, Ana, Ellard, Susan, de Braud, Filippo, Arkenau, Hendrik-Tobias, Trigo, José, Gravina, Adriano, Kristeleit, Rebecca, Moreno, Victor, Abdeddaim, Cyril, Vano, Yann-Alexandre, Samouëlian, Vanessa, Miller, Rowan, Boni, Valentina, Torres, Antonio Antón, Gilbert, Lucy, Brown, Jubilee, Dewal, Ninad, Dabrowski, Christine, Antony, Grace, Zografos, Eleftherios, Veneris, Jennifer, Banerjee, Susana

“…Mismatch repair deficiency (dMMR) occurs in various cancers, and these tumors are attractive candidates for anti-programmed cell death 1 therapies, such as…”
Get full text

Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts by Camps Herrero, Carlos, Antón Torres, Antonio, Cruz-Hernández, Juan Jesús, Carrato, Alfredo, Constenla, Manuel, Díaz-Rubio, Eduardo, Feyjoo Saus, Margarita, Garcia-Foncillas, Jesus, Gascón, Pere, Guillem, Vicente

“…There is a lack of standards for the diagnosis, assessment and management of breakthrough cancer pain (BTcP). La Fundación ECO (the Foundation for Excellence…”
Get full text

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer by Alba, Emilio, Lluch, Ana, Ribelles, Nuria, Anton‐Torres, Antonio, Sanchez‐Rovira, Pedro, Albanell, Joan, Calvo, Lourdes, García‐Asenjo, Jose Antonio Lopez, Palacios, Jose, Chacon, Jose Ignacio, Ruiz, Amparo, De la Haba‐Rodriguez, Juan, Segui‐Palmer, Miguel A., Cirauqui, Beatriz, Margeli, Mireia, Plazaola, Arrate, Barnadas, Agusti, Casas, Maribel, Caballero, Rosalia, Carrasco, Eva, Rojo, Federico

Get full text

Patient Perspective on the Management of Cancer Pain in Spain by García-Foncillas, Jesús, Antón-Torres, Antonio, Caballero-Martínez, Fernando, Campos, Francisco J, Feyjoo, Margarita, de Liaño, Alfonso Gómez, Monge, Diana, Camps, Carlos

“…Pain in cancer is often underdiagnosed and undertreated. Breakthrough pain, in particular, severely impacts the quality of life of patients. In this study, we…”
Get full text

Gene expression profiling and its use in adenocarcinomas of unknown primary origin: A case report by DE MIGUEL, ANA CEBOLLERO, CID, ROBERTO PAZO, TRUFERO, JAVIER MARTINEZ, BERNAD, ISABEL PAJARES, URQUIZU, LOURDES CALERA, CUBERO, JORGE HERNANDO, TORRES, ANTONIO ANTON

“…Carcinomas of unknown primary origin account for 3-5% of all malignancies. The current literature suggests that metastatic dissemination is able to occur in…”
Get full text

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY by Balmaña, Judith, Fasching, Peter A., Couch, Fergus J., Delaloge, Suzette, Labidi-Galy, Intidhar, O’Shaughnessy, Joyce, Park, Yeon Hee, Eisen, Andrea F., You, Benoit, Bourgeois, Hughes, Gonçalves, Anthony, Kemp, Zoe, Swampillai, Angela, Jankowski, Tomasz, Sohn, Joo Hyuk, Poddubskaya, Elena, Mukhametshina, Guzel, Aksoy, Sercan, Timcheva, Constanta V., Park-Simon, Tjoung-Won, Antón-Torres, Antonio, John, Ellie, Baria, Katherine, Gibson, Isabel, Gelmon, Karen A.

“…Purpose The interim analysis of the phase IIIb LUCY trial demonstrated the clinical effectiveness of olaparib in patients with germline BRCA-mutated (gBRCAm),…”
Get full text

Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial by Moreno, Victor, Barretina-Ginesta, Maria-Pilar, García-Donas, Jesús, Jayson, Gordon C, Roxburgh, Patricia, Vázquez, Raúl Márquez, Michael, Agnieszka, Antón-Torres, Antonio, Brown, Richard, Krige, David, Champion, Brian, McNeish, Iain

“…BackgroundTreatment outcomes remain poor in recurrent platinum-resistant ovarian cancer. Enadenotucirev, a tumor-selective and blood stable adenoviral vector,…”
Get full text

Delayed and Long-Lasting Response to 177Lu-DOTATATE in a Head and Neck Paraganglioma: Case Report and Literature Review by Ruffini Egea, Sofía, Campos Ramírez, Sara Elena, Pascual de la Fuente, Natalia Pilar, Monreal Cepero, María Luna, Mocha Campillo, Fatima, Trincado Cobos, Pablo, Antón Torres, Antonio, Martínez Trufero, Javier

“…Malignant paragangliomas (M-PGL) are a group of neuroendocrine tumors that originate from chromaffin cells. The most common location for PGL is the head and…”
Get full text

Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study by de Dueñas, Eduardo Martínez, Hernández, Ana Lluch, Zotano, Ángel Guerrero, Carrión, Ramón María Pérez, López-Muñiz, José Ignacio Chacón, Novoa, Silvia Antolín, Rodríguez, Ángela López, Fidalgo, José Alejandro Pérez, Lozano, Jaime Ferrer, Gasión, Octavio Burgués, Carrascal, Eva Carrasco, Capilla, Andrés Hernando, López-Barajas, Isabel Blancas, Mateu, Montserrat Muñoz, de Ceballos Reyna, María Helena López, Ferrando, Amparo Oltra, Jañez, Noelia Martínez, Ballerini, Vicente Carañana, Torres, Antonio Antón, Catalán, Gustavo, Sáenz, José Ángel García, Menjón, Salomón, González-Angulo, Ana María

“…The objective of this study was to determine the conversion rate of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER) and progesterone…”
Get full text

Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study by Llombart-Cussac, Antonio, Anton-Torres, Antonio, Rojas, Beatriz, Andrés, Raquel, Martinez, Noelia, Rodríguez, César A, Marin, Sara, Puértolas, Teresa, González, Alejandro Falcón, Fernández-Murga, María Leonor, Hagen, Carlos, Ruiz-Borrego, Manuel

“…The 21-gene Oncotype DX Breast Recurrence Score assay is prognostic and predictive of chemotherapy benefit for patients with estrogen receptor-positive, HER2-…”
Get full text

A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01 by Bellmunt, Joaquim, Maroto-Rey, Pablo, Trigo, José M., Carles, Joan, Guillem, Vicente, López-Martín, José A., Antón-Torres, Antonio, Urruticoechea, Leyrer

“…Aims Our aim was to evaluate first-line treatment of metastatic renal cell carcinoma (mRCC) with sorafenib in patients unwilling to receive immunotherapy or…”
Get full text

Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study by DE CASTRO CARPEÑO, JAVIER, GASCÓN-VILAPLANA, PERE, TEJERINA, ANA MARIA CASAS-FERNÁNDEZ-DE, ANTÓN-TORRES, ANTONIO, LÓPEZ-LÓPEZ, RAFAEL, BARNADAS-MOLINS, AGUSTÍ, CRUZ-HERNÁNDEZ, JUAN JESÚS, MASSUTI-SUREDA, BARTOMEU, CAMPS-HERRERO, CARLOS, ARANDA-AGUILAR, ENRIQUE, LASERNA, FRANCISCO JOSÉ REBOLLO

“…Febrile neutropenia (FN) is one of the most common adverse events associated with myelosuppressive chemotherapy for cancer treatment. The objective of this…”
Get full text

Role of low molecular weight heparins in prophylaxis of thromboembolic events on oncological patients with indwelling central venous catheter by Calderero Aragón, Verónica, de Gregorio Ariza, Miguel Angel, Pazo Cid, Roberto, Puértolas Hernández, Teresa, Lostalé Latorre, Fernando, Artal Cortés, Angel, Antón Torres, Antonio

“…Our study was designed to assess the incidence of thrombosis in the upper limbs and of pulmonary embolism in oncological patients with indwelling central…”
Get more information

Brain metastasis in basaloid undifferentiated anal carcinoma: A case report by HERNANDO-CUBERO, JORGE, ALONSO-ORDUÑA, VICENTE, HERNANDEZ-GARCIA, ALBA, DE MIGUEL, ANA CEBOLLERO, ALVAREZ-GARCIA, NATALIA, ANTON-TORRES, ANTONIO

“…Anal cancer is a rare tumor that accounts for 2% of all colorectal neoplasms. The brain is a rarely affected organ. The aim of the present study was to the…”
Get full text

The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer by Dugo, Matteo, Huang, Chiun-Sheng, Egle, Daniel, Bermejo, Begoña, Zamagni, Claudio, Seitz, Robert S, Nielsen, Tyler J, Thill, Marc, Antón-Torres, Antonio, Russo, Stefania, Ciruelos, Eva Maria, Schweitzer, Brock L, Ross, Douglas T, Galbardi, Barbara, Greil, Richard, Semiglazov, Vladimir, Gyorffy, Balázs, Colleoni, Marco, Kelly, Catherine M, Mariani, Gabriella, Del Mastro, Lucia, Blasi, Olivia, Callari, Maurizio, Pusztai, Lajos, Valagussa, Pinuccia, Viale, Giuseppe, Gianni, Luca, Bianchini, Giampaolo

“…We assessed the 27-gene RT-qPCR-based DetermaIO assay and the same score calculated from RNA sequencing (RNA-seq) data as predictors of sensitivity to immune…”
Get full text

Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient non-endometrial solid tumors: A post-hoc subgroup analysis of patients with colorectal cancer by Andre, Thierry, De Braud, Filippo G., Jimenez-Rodriguez, Begona, Berton, Dominique, Curigliano, Giuseppe, Arkenau, Tobias, Antón Torres, Antonio, Paez, David, Ellard, Susan, Abdeddaim, Cyril, Castanon Alvarez, Eduardo, Aubin, Francine, Duan, Tao, Veneris, Jennifer Taylor, Zografos, Eleftherios, Starling, Naureen

“…Abstract only 201 Background: Dostarlimab is a programmed death receptor-1 (PD-1) blocking antibody that is approved in the US as a monotherapy in adult…”
Get full text

Safety of trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (mBC): Final results from KAMILLA Cohorts 1 (global) and 2 (Asia) by Wuerstlein, Rachel, Ellis, Paul, Montemurro, Filippo, Antón Torres, Antonio, Delaloge, Suzette, Zhang, Qingyuan, Wang, Xiaojia, Wang, Shusen, Zhimin, Shao, Li, Huiping, Rachman, Andhika, Vongsaisuwon, Mawin, Liu, Haiying, Fear, Simon, Pena-Murillo, Claudia, Barrios, Carlos H.

“…Abstract only 1039 Background: KAMILLA is an open-label, single-arm, phase 3b safety study of T-DM1 in pts with HER2-positive advanced BC (NCT01702571). The…”
Get full text